The FDA's clinical hold on RAPT Therapeutics' key trials led to a significant stock price drop, reflecting investor concerns over the future of the company's drug development. The subsequent rebound suggests a volatile market response, while analyst downgrades indicate skepticism about the company's ability to quickly resolve these issues. The short-term impact is neutral due to the balance between the initial drop and the rebound, but the situation remains fluid and could change based on future developments.